Chad Jennings is an associate in the Washington, D.C. office of Latham & Watkins and a member of the Healthcare & Life Sciences Practice. He focuses his practice on regulatory matters involving the Food and Drug Administration (FDA) and transactional matters involving the life sciences industry. 

In particular, Mr. Jennings' practice is focused on transactional and regulatory matters involving the medical device, biotechnology, food, dietary supplement and cosmetic industries. Mr. Jennings has advised clients on diligence issues related to their most complex corporate transactions, including in understanding and assessing risks involved in all stages of the biotechnology product life cycle, such as:

  • Pre-market product development and clinical and pre-clinical testing
  • Product submissions
  • Product promotion and labeling
  • Compliance with manufacturing practice requirements
  • Agency inspections and recalls

He represents leading banks and clients throughout the healthcare and life sciences industry including pharmaceutical and medical device manufacturers, and frequently advises on regulatory matters in connection with capital markets and M&A transactions involving FDA-regulated entities. Mr. Jennings regularly conducts diligence for major public and private financings, equity offerings and other transactions in the pharmaceutical, device and biotechnology sectors.

While in law school, Mr. Jennings was on the editorial board of the Virginia Sports and Entertainment Law Journal. Mr. Jennings also served as a judicial intern for Judge Norman K. Moon at the United States District Court for the Western District of Virginia. Before law school, Mr. Jennings performed consulting work for a liberal arts college developing undergraduate business curriculum and research materials relating to finance and international investment.

Mr. Jennings' experience includes representing: 

  • Issuers and underwriters in connection with regulatory matters in capital markets transactions in the life sciences and healthcare industries, including initial public offerings and equity follow-on offerings
  • Purchasers and borrowers in connection with financings and mergers and acquisitions involving FDA-regulated entities
  • Pharmaceutical and medical device manufacturers in the preparation and filing of FDA submissions

Mr. Jennings' representative transactions include advising:

  • ICU medical in its US$1 billion acquisition of the Hospira Infusion Systems business of Pfizer
  • Inova Labs, Inc. in its US$110 million sale to ResMed Inc.
  • Kohlberg Kravis Roberts & Co. L.P. (KKR) in a US$25 million investment in Cereve Inc.
  • J.P. Morgan and Cowen and Company, LLC in US$132 million offering by Array Biopharma, Inc.
  • Credit Suisse and Jefferies in a US$96 million initial public offering by ObsEva SA
  • Goldman Sachs and Morgan Stanley in US$144 million and US$230 million follow-on offerings by Blueprint Medicines
  • Achaogen inc in its US$100 follow-on offering of its common stock
  • Entellus Medical, Inc. in its US$60 million offering of its common stock

Bar Qualification

  • District of Columbia
  • Massachusetts

Education

  • JD, University of Virginia School of Law, 2014
    Order of the Coif
  • MA, University of Virginia, 2007
  • BA, Virginia Polytechnic Institute and State Univ., 2005
    summa cum laude